Curated dataset · n=61 verified deals · Not live market data · Scores are descriptive, not forecasts.
You are here

Intelligence — Reimbursement context, historical acquirer-profile overlap, and dataset export.

Intelligence workspace

Reimbursement context, historical acquirer-profile overlap, and export tools. Overlap indexes are descriptive heuristics — they do not feed deal economics, valuation peers, or dual-source badges.

System Health & Monitoring

Live API checks plus the measurement-layer census: quality grades, withheld metrics, vintage gaps, and display provenance.

Loading dashboard section

Data Pipeline Status

Counts and grades from verified artifacts — no fabricated latency or invented completion percentages.

61
Verified deals
152
Company records
31 days since last update
Dataset as of 2026-10-19
SEC EDGAR ingest
Not configured (static dataset)
Not configured
Source-quality grades
Companies avg 64.0 · deals avg 87.0
Provenance instrumentation
21 / 911 (2.3%)
SEC operating revenue
MeshIC audit found issuer/CIK identity mismatches in the prior artifact. The stale records were removed rather than left available to downstream analysis. Regenerate with scripts/fetch-sec-revenue.ts, which now validates SEC registrant identity before accepting facts.
Withheld
Operating growth rates
SEC revenue evidence is currently withheld pending identity-validated regeneration. Financing-derived and valuation-derived rates are not substituted for operating growth.
Withheld
CMS utilization
No verified CMS aggregate observations are committed. Sector reimbursement totals stay null rather than using mean-payment fallback arithmetic.
Withheld

Dataset version v11. Grades and coverage come from computed-data-quality-scores.json and provenance-baseline.json, hash-verified on every push. SEC ingest uses live loadSummaryPipelines when LACUNA_DATA_MODE=db.

Measurement layer

Quality grades, gated-metric publication, vintage gaps, and display provenance — read from computed artifacts, not a hardcoded pipeline panel.

Published (4/4 fully provenanced)
Withheld of 209 (98.1%)
Missing dedicated as-of (68/137)
Uncovered display sites of 911

Company source quality

avg

A 3B 39C 44D 58F 8

Deal source quality

avg

A 28B 5C 23D 1F 4

44/98 active economic records. 31 are current-only because publicAsOfDate is missing (totalFunding 22/40, lastKnownValuation 9/58). Missing dates stay missing.

/47 computedPremium rows exactly reproducible · Deal values use announcement date only (52/52) — not a value vintage. · Pre-deal valuations with date: 49/49.

Most uncovered numeric render files

  • src/components/WhiteSpaceAnalysis.tsx86
  • src/components/NetworkAnalysisHonest.tsx83
  • src/components/StrategicPositioningMap.tsx61
  • src/app/sections/PayerOpsPage.tsx49
  • src/components/FairnessAuditV2.tsx46
  • src/components/CompetitiveAnalysisDashboard.tsx33
  • src/components/FounderCharacteristics.tsx33
  • src/components/GenderInferenceQuality.tsx26

Artifact v11 · hash 5a0a432d5db8 · 2026-10-19T00:00:00.000Z · 66 companies and 5 deals graded D/F

Reimbursement & Commercial Due Diligence

Verified deal context by sector from the curated dataset — no invented TAM, payer mix, or keyword risk scores. The SA051 card is an investigation target, not a payment conclusion.

Loading dashboard section
Loading dashboard section

Catalyst watchlist

Weekly biopharma calendar joined to Lacuna's verified acquirer and company ids. Dates are scheduled PDUFA/readout marks with an actual date when the decision already happened.

Women's-health relevant

12 of 85 weekly catalysts are tagged women's-health relevant. The current feed is general biopharma; Lacuna IDs are filled only when the company is already in the verified universe.

ScheduledCompanyEventStatusBasis
2026-09-04actual 2026-09-04AstraZenecaEtcamah (camizestrant)approvalESR1-mutated HR+/HER2- advanced or metastatic breast cancerapprovedactual_event · dayBreast HealthNCT04964934
2026-09-10actual 2026-09-10AbbVieatogepant (QULIPTA/AQUIPTA)readoutpreventive treatment of menstrual migrainepositiveactual_event · dayTherapeutics
2026-09-17actual 2026-09-17Biosimilar Collaborations Irelandpertuzumab biosimilar (Pebrilzo)CHMPHER2-positive early and metastatic breast cancerpositiveactual_event · dayBreast Health
2026-09-17actual 2026-09-17Corcept Therapeuticsrelacorilant (Lifyorli)CHMPplatinum-resistant high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer, with nab-paclitaxelpositiveactual_event · dayTherapeuticsNCT05257408
2026-09-17actual 2026-09-17SFL Pharmaceuticals Deutschlandsenaparib (Sepalna)CHMPmaintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancerpositiveactual_event · dayTherapeutics
2026-09-25actual 2026-09-25SimBioSysTumorSight Risk (510(k))approval5- and 10-year recurrence risk, HR+/HER2- stage I-IIIA breast cancerapprovedactual_event · dayBreast Health
2026-10-07actual 2026-10-07PfizerTukysa (tucatinib)Seagen → PfizerapprovalHER2+ metastatic breast cancer, first-line maintenance with trastuzumab and pertuzumab (HER2CLIMB-05)approvedactual_event · dayacquirer-pfizer · Breast HealthNCT05132582
2026-10-15actual 2026-10-15PfizerTukysa (tucatinib) extensionSeagen → PfizerCHMPmaintenance with trastuzumab + pertuzumab in HER2+ unresectable/metastatic breast cancer after 1L inductionpositiveactual_event · dayacquirer-pfizer · Breast HealthNCT05132582
2026-11-30Rochegiredestrant (adjuvant)PDUFAER+/HER2- stage I-III early breast cancer (lidERA)upcomingthird_party_calendar · dayacquirer-roche · Breast HealthNCT04961996
2026-12-18Rochegiredestrant + everolimusPDUFAESR1-mutated ER+/HER2- advanced breast cancer (evERA)upcomingthird_party_calendar · dayacquirer-roche · Breast HealthNCT05306340
2027-04-01BayerLynkuet (elinzanetant) sNDAKaNDy Therapeutics → BayerPDUFAvasomotor symptoms from endocrine therapy for HR+ breast cancer (OASIS-4)upcomingestimated · quarteracquirer-bayer · MenopauseNCT05587296
2027-04-01Organon/Sebela Women's HealthMIUDELLA (copper intrauterine system)PDUFAprevention of pregnancy - extension of duration of use to 6 yearsupcomingcompany_guidance · quarteracquirer-organon · Contraception

Tracked acquirers / companies · next 90 days

2 scheduled events in 2026-11-19 → 2027-02-17 for Roche, J&J, GRAIL, or another verified id.

ScheduledCompanyEventStatusBasis
2026-11-30Rochegiredestrant (adjuvant)PDUFAER+/HER2- stage I-III early breast cancer (lidERA)upcomingthird_party_calendar · dayacquirer-roche · Breast HealthNCT04961996
2026-12-18Rochegiredestrant + everolimusPDUFAESR1-mutated ER+/HER2- advanced breast cancer (evERA)upcomingthird_party_calendar · dayacquirer-roche · Breast HealthNCT05306340

Acquirer Fit & Precedent Map

Verified acquirer profiles and same-sector historical deals beside a company. Historical exits are not an acquisition prediction, and a missing price is not zero.

Loading dashboard section

Export & share

Download the verified dataset in JSON, CSV, or Parquet.

Loading dashboard section

Developer Tools

API documentation, SDK references, code examples, and integration guides for engineers building on the Lacuna platform.

Loading dashboard section